Si l'on vous a dit que vous aviez une stéatose hépatique, la première chose à savoir est qu'elle fait partie des affections chroniques les plus réversibles qui soient. Les leviers qui l'inversent sont des leviers quotidiens ordinaires que vous contrôlez déjà. Perdez du poids et la graisse du foie disparaît chez la plupart des gens, l'inflammation se calme, et dans certains cas même une fibrose précoce régresse. Un régime méditerranéen, l'activité physique, le café et la réduction des boissons sucrées abaissent chacun la graisse du foie à eux seuls.
La constance compte plus que le choix. Des médicaments existent désormais pour la forme inflammatoire — le resmétirom, approuvé en 2024, ainsi que le sémaglutide et le tirzépatide. Ils viennent après les bases, pour les personnes qui ont travaillé leurs habitudes et ont besoin de plus.
Practice Ranking
Every practice we track for Fatty Liver Disease (NAFLD / MASLD): what to do first, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
7 practices · 4 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Weight Loss: The Single Strongest Lever for Metabolic Health, and What the Trials Actually Show A 10% loss resolved steatohepatitis in about 90%. | Strong | Self-Directed | Free to $$$ | Moderate to Hard | Weeks to Months | |
| 2 | The Mediterranean Diet: What It Does, Why It Works, and How to Start A Mediterranean diet cut liver fat by about a third even without weight loss, making it the food pattern to start from. | Moderate | Self-Directed | $ to $$ | Moderate | Months to Longer | |
| 3 | Zone 2 Cardio: What the Training Does, and Where the Claims Run Ahead of the Evidence Aerobic and resistance exercise both lower liver fat even when body weight does not change, so movement counts on its own. | Moderate | Self-Directed | Free to $$ | Moderate | Weeks to Months | |
| 4 | Whole Foods and Ultra-Processed Foods: What the Evidence Shows and How to Eat Well Cutting added sugar for eight weeks dropped liver fat from about 25% to 17%, and sugary drinks raise the risk of fatty liver with each serving. | Moderate | Self-Directed | $ to $$ | Moderate to Hard | Weeks to Months | |
| 5 | GLP-1 Medications: What They Do, the Trade-offs, and How to Use Them Well Semaglutide resolved steatohepatitis in 63% against 34% on placebo and improved scarring, and tirzepatide reached up to 62%; both trials were funded by their makers, Novo Nordisk and Eli Lilly. | Strong | Pro | $$$ | Easy to Moderate | Weeks to Months | |
| 6 | Caffeine: What It Does, the One Catch for Sleep, and How to Use It Well Coffee drinkers, including decaf, had about 35% lower odds of significant liver scarring. | Moderate | Self-Directed | Free to $ | Easy | Days | |
| 7 | Berberine: What It Does for Blood Sugar and Cholesterol Berberine lowered liver enzymes, liver fat, blood sugar and cholesterol alongside lifestyle change, an early but consistent signal. | Emerging | Supplement | $ | Easy | Days to Weeks | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Fatty liver is fat stored inside the liver cells of a person who does not drink heavily. It is the most common chronic liver condition in the world, affecting about one in four adults.
Most people with fatty liver feel completely well, so it is usually caught by accident on an ultrasound or on liver blood tests run for something else. Because the four stages cannot be told apart by how you feel, doctors follow up on a raised liver enzyme or a fibrosis score that stays high.
The mildest is simple fat, with little or no inflammation. It is the most reversible stage, since the fat clears in most people who lose weight. Steatohepatitis adds inflammation and cell injury, and can scar the liver over years. Fibrosis, the scarring stage, is the one that decides how things turn out over the long run, though early fibrosis can still pull back with sustained weight loss. Cirrhosis is advanced scarring that needs monitoring for complications.
The insulin resistance that stores liver fat also drives type 2 diabetes and heart disease.
Most people with fatty liver die of a heart attack before the liver becomes the problem.
Two situations are exceptions. Fatty liver appears in some people who are not overweight, more often in South and East Asian backgrounds. In others, the liver enzymes keep climbing. In either case, get checked so another cause is not missed.
What helps the liver
The levers that reverse fatty liver are ordinary daily habits. Weight loss is the biggest of the six.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Measurement And Diagnosis
Environ un adulte sur quatre dans le monde a un foie gras
Environ une personne sur quatre dans le monde présente une accumulation de graisse dans le foie, et pour la plupart d'entre elles, le plus grand danger pour la vie est la maladie cardiaque, non le foie lui-même.
La prévalence mondiale regroupée de la stéatose hépatique non alcoolique était de 25.24 % (IC à 95 % de 22.10 à 28.65). Parmi les personnes atteintes ayant subi une biopsie pour une raison clinique, 59.10 % avaient une stéatohépatite, et la maladie cardiovasculaire était une cause majeure de décès, devant les causes spécifiques au foie. Measured in: Meta-analysis of 86 studies covering 8,515,431 people across 22 countries, imaging- and biopsy-based. La prévalence varie largement selon la région et la méthode de diagnostic, et le chiffre plus élevé de stéatohépatite provient de personnes biopsiées parce que quelque chose semblait anormal, ce qui surestime la part parmi l'ensemble des personnes présentant de la graisse dans le foie. L'estimation est antérieure au renommage MASLD de 2023.
Who this may not transfer to:A pooled global figure; prevalence runs higher in the Middle East and South America and lower in Africa, so the single number describes the world, not your neighborhood.
The study · 1
Younossi et al., global epidemiology of nonalcoholic fatty liver disease, meta-analytic assessment of prevalence, incidence, and outcomes · Hepatology 2016;64(1):73-84
Liver
La vitamine E a amélioré la stéatohépatite chez 43 % des non-diabétiques, contre 19 % sous placebo
Chez les personnes non diabétiques, une dose quotidienne élevée de vitamine E a amélioré l'inflammation hépatique chez environ 43 % d'entre elles, contre 19 % sous placebo.
La vitamine E à 800 UI par jour a amélioré la stéatohépatite chez 43 % des patients contre 19 % sous placebo sur environ 2 ans (p=0.001), et a réduit les enzymes hépatiques. La pioglitazone a également amélioré plusieurs mesures mais n'a pas atteint le seuil préspécifié de l'essai pour le critère de jugement principal. Measured in: 247 adults with biopsy-proven non-alcoholic steatohepatitis and without diabetes, in the PIVENS randomized placebo-controlled trial. Le bénéfice a été démontré chez des personnes non diabétiques ; le bras médicamenteux et la population diabétique sont des questions distinctes. La vitamine E à forte dose sur le long terme a été associée dans d'autres essais à une légère augmentation du risque de cancer de la prostate chez l'homme et à un risque d'accident vasculaire cérébral hémorragique, si bien que la dose et la personne comptent, et il s'agit d'une décision à prendre avec un clinicien après les bases alimentaires et d'activité physique.
Who this may not transfer to:Non-diabetic adults with biopsy-proven steatohepatitis; the result does not automatically extend to people with diabetes or to simple fat without inflammation.
The study · 1
Sanyal et al., pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS) · N Engl J Med 2010;362(18):1675-85
La pioglitazone a fait disparaître la stéatohépatite chez environ la moitié des personnes diabétiques ou prédiabétiques, contre moins d'1 sur 5 sous placebo
Chez les personnes diabétiques ou prédiabétiques, le médicament pioglitazone a fait disparaître l'inflammation hépatique chez environ la moitié d'entre elles, contre moins d'une sur cinq sous placebo.
La pioglitazone à 45 mg par jour a atteint le critère de jugement principal, une baisse de 2 points ou plus du score d'activité sans aggravation de la fibrose, chez 58 % contre 17 % sous placebo, et a résolu la stéatohépatite chez 51 % contre 19 %, sur 18 mois. Measured in: 101 adults with prediabetes or type 2 diabetes and biopsy-proven non-alcoholic steatohepatitis, randomized to pioglitazone or placebo alongside a hypocaloric diet. Les deux groupes suivaient aussi un régime hypocalorique, si bien que l'effet du médicament s'ajoute au changement de mode de vie, sans le remplacer. La pioglitazone provoque couramment une certaine prise de poids et une rétention d'eau, et elle est évitée en cas d'insuffisance cardiaque, si bien que c'est un choix réfléchi pour la bonne personne, pas un défaut par défaut.
Who this may not transfer to:Studied specifically in people with impaired glucose handling, the group in whom pioglitazone is most relevant; it was layered on a calorie-reduced diet.
The study · 1
Cusi et al., long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus, a randomized trial · Ann Intern Med 2016;165(5):305-15
Semaglutide cleared steatohepatitis in 59% against 17% on placebo, without clearly easing scarring
Le médicament GLP-1 sémaglutide a fait disparaître l'inflammation hépatique chez environ 59 % des personnes contre 17 % sous placebo, bien qu'il n'ait pas clairement amélioré la cicatrisation qui compte le plus sur le long terme.
Le sémaglutide quotidien à 0.4 mg a résolu la stéatohépatite sans aggraver la fibrose chez 59 % contre 17 % sous placebo sur 72 semaines. L'amélioration du stade de fibrose lui-même n'était pas significativement différente entre les groupes, à 43 % contre 33 %. Measured in: 320 adults with biopsy-proven non-alcoholic steatohepatitis and fibrosis stage 1 to 3, in a phase 2 placebo-controlled trial. The inflammation resolved but the scarring stage did not shift significantly over 72 weeks, which matters because fibrosis is what drives long-term outcome. Nausea and other gut effects were common. This is a drug that comes after the habits, not a substitute for them.
Who this may not transfer to:A phase 2 trial in people with confirmed steatohepatitis and early-to-moderate fibrosis; it shows resolution of inflammation, with the harder fibrosis endpoint still open.
The study · 1
Newsome et al., a placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis · N Engl J Med 2021;384(12):1113-24
Resmetirom cleared steatohepatitis in a quarter to a third and eased scarring in about a quarter
Over a year the newer drug resmetirom cleared liver inflammation in roughly a quarter to a third of people and eased scarring in about a quarter, both better than a dummy pill, though most people on it did not reach either mark.
Over 52 weeks, steatohepatitis resolved without worsening fibrosis in 25.9% (80 mg) and 29.9% (100 mg) against 9.7% on placebo, and fibrosis improved by at least one stage in 24.2% and 25.9% against 14.2% on placebo. Both endpoints were met. Measured in: 966 adults with biopsy-confirmed steatohepatitis and fibrosis stage 1 to 3 in the MAESTRO-NASH phase 3 trial. This is the drug behind the 2024 approval, and it is the first to move both inflammation and fibrosis in a phase 3 trial, though most participants on the drug still did not reach either endpoint, and it was studied on top of standard lifestyle advice, not instead of it. Long-term outcome data, whether it prevents cirrhosis and death, is still being gathered.
Who this may not transfer to:Studied in confirmed steatohepatitis with fibrosis; it is not a treatment for simple fat without inflammation, and it was added to, not instead of, lifestyle change.
The study · 1
Harrison et al., a phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH) · N Engl J Med 2024;390(6):497-509
Semaglutide resolved steatohepatitis in 63% vs 34% and improved scarring in 37% vs 22% (phase 3)
In the large phase 3 trial the higher dose of semaglutide cleared liver inflammation in about 63% of people, against 34% on a dummy pill, and this time it also eased the scarring, in about 37% against 22%.
At week 72, steatohepatitis resolved without worsening of fibrosis in 62.9% on weekly semaglutide 2.4 mg against 34.3% on placebo (a 28.7 point difference, P<0.001), and fibrosis improved by at least one stage without worsening of steatohepatitis in 36.8% against 22.4% on placebo (a 14.4 point difference, P<0.001). Weight fell by 10.5% against 2.0%. Measured in: Interim 72-week biopsy analysis of the first 800 of 1,197 adults with biopsy-confirmed steatohepatitis and fibrosis stage 2 or 3, randomized to weekly semaglutide 2.4 mg or placebo, in the phase 3 ESSENCE trial. This phase 3 trial reached both endpoints, including the fibrosis improvement that the earlier phase 2 trial had left open, in a much larger group. It is an interim biopsy analysis at 72 weeks within a study that continues to 240 weeks for clinical outcomes, so whether it prevents cirrhosis and death is still being measured. Gastrointestinal effects were more common on the drug. It sits on top of the diet and activity work, and it was studied alongside lifestyle advice.
Who this may not transfer to:The 72-week biopsy result comes from the first 800 participants of a 1,197-person trial; it confirms that both the inflammation and the scarring move, with the long-term clinical-outcome phase still running to 240 weeks.
The study · 1
Sanyal et al., phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE) · N Engl J Med 2025;392(21):2089-2099
Perdre 10 % du poids corporel a fait disparaître la stéatohépatite chez environ 90 %, atténué la fibrose chez 45 %
Les personnes ayant perdu au moins un dixième de leur poids corporel en un an ont vu l'inflammation du foie disparaître dans environ neuf cas sur dix, et la fibrose s'est atténuée dans près de la moitié des cas ; plus la perte de poids était importante, meilleur était le résultat.
Parmi les personnes ayant perdu 10 % ou plus de leur poids corporel sur 52 semaines de changement de mode de vie, la stéatohépatite a régressé chez 90 %, la fibrose a régressé chez 45 %, et toutes ont connu une certaine réduction du score d'activité NAFLD. Le bénéfice suivait l'ampleur de la perte de poids : la résolution de la stéatohépatite était bien moins fréquente en dessous de 5 % de perte. Measured in: 293 patients with biopsy-proven non-alcoholic steatohepatitis who underwent a second liver biopsy after 52 weeks of a diet and exercise program. What could explain it instead: Self-selection by success. Whatever lets a person lose 10% of their weight in a year, more support, better health, more resources, may independently favor liver recovery, so the achieved-weight-loss gradient would look similar even if part of the effect were not the weight itself.. Il s'agit d'une étude à bras unique sans groupe témoin, de sorte que toute la cohorte tentait de changer en même temps et la comparaison se fait entre ceux qui ont réussi et ceux qui n'y sont pas parvenus. Seul environ un tiers a atteint 5 % de perte de poids et environ 1 sur 10 a atteint 10 %, si bien que les chiffres frappants reposent sur la minorité ayant atteint l'objectif le plus difficile.
Who this may not transfer to:A Cuban cohort with biopsy-confirmed steatohepatitis, so the reversal figures describe the inflammatory form specifically, and the achievers were a self-selected minority.
The study · 1
Vilar-Gomez et al., weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis · Gastroenterology 2015;149(2):367-78
Un régime méditerranéen a réduit la graisse hépatique d'environ un tiers sans perte de poids
Adopter un régime méditerranéen a réduit la graisse stockée dans le foie d'environ un tiers par rapport à un régime pauvre en graisses et riche en glucides, même lorsque les personnes ne perdaient pas de poids.
Un régime méditerranéen a réduit la graisse hépatique mesurée par spectroscopie par résonance magnétique d'environ 39 % par rapport à un régime pauvre en graisses et riche en glucides, et a amélioré la sensibilité à l'insuline, sur 6 semaines dans un schéma croisé où le poids était maintenu stable. Measured in: 12 non-diabetic adults with biopsy-proven non-alcoholic fatty liver disease, each acting as their own control across the two diets. Une très petite étude croisée portant sur 12 personnes sur une courte période, avec un poids délibérément maintenu constant, ce qui montre que le schéma alimentaire fait bouger la graisse hépatique à lui seul, mais pas l'ampleur ni la durabilité de l'effet à grande échelle. Des essais groupés plus larges depuis lors s'accordent sur la direction tout en montrant des changements moyens plus modestes.
Who this may not transfer to:Twelve people is a proof-of-mechanism sample, not a population estimate; read it as showing the pattern can move liver fat independent of weight, not as a precise effect size.
The study · 1
Ryan et al., the Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease · J Hepatol 2013;59(1):138-43
L'exercice a réduit la graisse hépatique même lorsque le poids corporel n'a pas changé
L'exercice régulier a réduit la graisse dans le foie même lorsque le poids corporel restait le même, si bien que le bénéfice ne dépend pas du déplacement de l'aiguille sur la balance.
En regroupant des essais où l'alimentation et le poids corporel étaient maintenus stables, l'exercice à lui seul a réduit la graisse stockée dans le foie et amélioré des marqueurs cliniques associés, si bien que le bénéfice ne dépend pas du déplacement de l'aiguille sur la balance. Measured in: Systematic review and meta-analysis of randomized controlled trials of exercise interventions in people with non-alcoholic fatty liver disease, restricted to trials without significant weight loss or dietary change. Les essais individuels sont pour la plupart petits et courts, et le volume hebdomadaire total, l'intensité et l'observance variaient entre eux, si bien que le résultat groupé confirme une direction plus solidement qu'il ne fixe une dose. L'exercice fait bouger la graisse hépatique davantage et plus vite lorsque le poids diminue également.
Who this may not transfer to:Pooled across trials that deliberately excluded weight loss, so it isolates the movement itself; the everyday case, moving and losing weight together, does better than either alone.
The study · 1
Babu et al., positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters, a systematic review and meta-analysis · Nutrients 2021;13(9):3135
Les buveurs de café avaient environ 35 % de risque en moins de cicatrisation hépatique significative
Les personnes atteintes de stéatose hépatique qui buvaient du café avaient environ un tiers de risque en moins de présenter une cicatrisation hépatique sévère. La question de savoir si les buveurs de café étaient moins susceptibles de développer une stéatose hépatique n'est pas tranchée : la même analyse n'a trouvé aucune différence significative sur ce point.
En regroupant des études observationnelles, les buveurs de café atteints de stéatose hépatique avaient environ 35 % de chances en moins de fibrose hépatique significative (RR 0.65, IC à 95 % 0.54-0.78). Le café n'était pas associé de manière significative à une réduction du risque de développer une stéatose hépatique au départ, ni à sa fréquence. Measured in: Systematic review and meta-analysis of observational studies of coffee consumption in relation to non-alcoholic fatty liver disease incidence, prevalence and fibrosis. Il s'agit d'études observationnelles regroupées, qui montrent donc une association, non une preuve de causalité : les buveurs de café peuvent différer des non-buveurs de manières non entièrement mesurées, et la quantité et le type de café ont été enregistrés différemment selon les études. Cela plaide en faveur du maintien d'une habitude de café, pas de son adoption à forte dose pour le foie.
Who this may not transfer to:The signal is for regular coffee, not decaffeinated alone or sugary coffee drinks, and it is an association across populations, not a measured dose response.
The study · 1
Ebadi et al., effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis, systematic review with meta-analysis of observational studies · Nutrients 2021;13(9):2947
L'éviction du sucre ajouté pendant 8 semaines a fait passer la graisse hépatique d'environ 25 % à 17 %
Chez les adolescents, huit semaines d'éviction du sucre ajouté ont fait passer la graisse hépatique d'environ 25 % à 17 %, alors qu'elle a à peine changé avec le régime habituel.
Un régime pauvre en sucre libre (moins de 3 % des calories quotidiennes) pendant 8 semaines a réduit la graisse hépatique mesurée par IRM de 25 % à 17 %, contre pratiquement aucun changement avec le régime habituel (21 % à 20 %), une différence significative en faveur de la restriction en sucre. Measured in: 40 adolescent boys aged 11 to 16 with biopsy- or imaging-confirmed non-alcoholic fatty liver disease, randomized to a low-free-sugar diet delivered to their homes or their usual diet. Le régime d'intervention a été préparé et livré aux familles, ce qui représente plus de soutien qu'une famille n'en aurait habituellement, et l'essai n'a duré que 8 semaines dans un groupe spécifique, des adolescents de sexe masculin, si bien que le chiffre exact ne s'applique peut-être pas aux adultes ou aux femmes. La direction, à savoir que le sucre ajouté favorise la graisse hépatique, est bien étayée par la biologie sous-jacente.
Who this may not transfer to:Studied only in adolescent boys with meals provided; the mechanism, fructose being converted to liver fat, applies broadly, but this precise effect size is not confirmed in adults or in girls and women.
The study · 1
Schwimmer et al., effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys, a randomized clinical trial · JAMA 2019;321(3):256-65
Five years after weight-loss surgery, steatohepatitis had cleared in about 84%
Five years after weight-loss surgery, liver inflammation had cleared in about 84% of people and the scarring had eased in most of them, including some severe cases.
Five years after bariatric surgery, steatohepatitis had resolved without worsening of fibrosis in 84% of patients with a repeat biopsy, and fibrosis had regressed in a majority, including reversal of some cases of advanced fibrosis. Measured in: 180 severely obese adults with biopsy-proven non-alcoholic steatohepatitis followed for 5 years after bariatric surgery, with serial liver biopsies. What could explain it instead: No control group and loss to follow-up. The people who returned for a 5-year biopsy are plausibly those doing better, and the surgery drives large sustained weight loss whose liver benefit cannot be separated from the operation itself.. This is a single-arm surgical cohort without a randomized comparison group, and only a subset had a full set of biopsies at 5 years, so the resolution figure describes those followed to the end, not everyone who started. Surgery carries its own operative and long-term nutritional consequences that sit outside this liver endpoint entirely.
Who this may not transfer to:A severely obese surgical cohort; the liver results are among the best reported, but they come with the risks and lifelong changes of the surgery and are not a lifestyle comparison.
The study · 1
Lassailly et al., bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis · Gastroenterology 2020;159(4):1290-1301
Tirzepatide resolved steatohepatitis in up to 62% of people vs 10% on placebo (phase 2)
The dual-hormone drug tirzepatide cleared liver inflammation in roughly half to two-thirds of people, against one in ten on a dummy pill, and eased scarring in about half, against roughly a third on placebo.
Over 52 weeks, steatohepatitis resolved without worsening of fibrosis in 44% (5 mg), 56% (10 mg) and 62% (15 mg) against 10% on placebo (all P<0.001), and fibrosis improved by at least one stage without worsening of steatohepatitis in 51 to 55% across the three doses against 30% on placebo. Measured in: 190 adults with biopsy-confirmed steatohepatitis and moderate to severe fibrosis (stage F2 or F3) randomized to weekly tirzepatide (5, 10 or 15 mg) or placebo, with 157 evaluable second biopsies at 52 weeks, in the phase 2 SYNERGY-NASH trial. This is a phase 2 dose-finding trial of about 190 people over a single year, so it establishes that the drug moves both inflammation and scarring while the larger phase 3 confirmation and long-term outcome data are still being gathered. Gastrointestinal effects such as nausea were the most common events, mostly mild to moderate. It is a drug that comes after the habits, and it was studied alongside standard lifestyle advice.
Who this may not transfer to:A phase 2 trial in confirmed steatohepatitis with moderate to severe fibrosis; it shows both the inflammation and the scarring endpoints moving, with phase 3 confirmation of durability and hard outcomes still in progress.
The study · 1
Loomba et al., tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH) · N Engl J Med 2024;391(4):299-310
Les boissons sucrées ont augmenté le risque de développer une stéatose hépatique, davantage à chaque portion
Les personnes qui consommaient plus souvent des boissons sucrées étaient plus susceptibles de développer une stéatose hépatique sur six ans, et le risque augmentait avec la consommation.
Sur 6 ans de suivi, les personnes qui buvaient plus souvent des boissons sucrées avaient un risque plus élevé de stéatose hépatique nouvelle et existante que celles qui en buvaient rarement, le risque augmentant avec la consommation. Measured in: Adults in the Framingham Heart Study Offspring and Third Generation cohorts, followed with liver fat assessed by CT and diet by questionnaire. What could explain it instead: People who drink a lot of sugary beverages tend to eat more calories overall, weigh more, and move less, and those factors also cause fatty liver, so part of the association reflects the whole dietary and lifestyle pattern, not the drink in isolation.. Une cohorte observationnelle, qui montre donc que la consommation de boissons sucrées va de pair avec la stéatose hépatique, non qu'elle en est la seule cause. Les sodas light, en revanche, n'étaient pas clairement protecteurs, ce qui concorde avec l'idée que le régime alimentaire environnant et le poids corporel portent une grande part du signal.
Who this may not transfer to:A predominantly white US community cohort; the direction is consistent with trial data on sugar, but the exact risk is specific to this population.
The study · 1
Park et al., sugar-sweetened beverage, diet soda, and nonalcoholic fatty liver disease over 6 years, the Framingham Heart Study · Clin Gastroenterol Hepatol 2022;20(11):2524-32
Berberine lowered liver enzymes, liver fat, blood sugar and cholesterol alongside lifestyle change
Berberine, the active compound in the bitter herb Coptis, improved liver enzymes, lowered liver fat, and helped blood sugar and cholesterol, usually alongside lifestyle changes.
Pooling randomized trials, berberine improved liver enzymes, reduced liver fat, and improved insulin resistance and blood lipids compared with control, often alongside lifestyle advice. Measured in: Meta-analysis of randomized controlled trials of berberine in adults with non-alcoholic fatty liver disease. The trials are mostly small, short, and run in China with varied quality and dosing, so the pooled benefit is promising, not settled, and long-term and biopsy outcomes are missing. Berberine can lower blood sugar and interacts with several medications, so it belongs with a practitioner, not self-stacked. It is the active compound in Coptis (Huang Lian), a bitter cold herb Chinese medicine uses to clear damp-heat, which fits the robust, inflamed presentation and not the tired, Spleen-deficient one.
Who this may not transfer to:Pooled largely from Chinese trials of varying quality; the direction is consistent but the effect size and durability are not yet confirmed in large, long, biopsy-based studies.
The study · 1
Nie et al., the clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease, a meta-analysis and systematic review · J Transl Med 2024;22(1):225
Milk thistle modestly lowered liver enzymes, with little reliable effect on liver fat
Milk thistle modestly lowered liver enzymes in the blood, with a smaller and less reliable effect on the fat in the liver itself.
Pooling randomized trials, silymarin modestly lowered the liver enzymes ALT and AST compared with control, with smaller and less consistent effects on liver fat itself. Measured in: Systematic review and meta-analysis of randomized controlled trials of silymarin in people with non-alcoholic fatty liver disease or steatohepatitis. The effect on enzymes is modest, and enzymes are a rough marker, not proof the underlying disease is reversing; the harder outcomes, inflammation and fibrosis on biopsy, are not established. Milk thistle has a long traditional record for the liver and a good safety profile, which is part of why it keeps being studied; it is a reasonable adjunct, not a replacement for the weight, diet and activity work.
Who this may not transfer to:Pooled trials use different silymarin preparations and doses, so the enzyme benefit is a class signal, not a guide to one specific product.
The study · 1
Li et al., administration of silymarin in NAFLD/NASH, a systematic review and meta-analysis · Ann Hepatol 2024;29(2):101174
Weight loss, the single biggest lever
Weight loss is the single biggest lever. It is what the habits above add up to when you keep them going for months. In a study that biopsied the liver before and after, people who lost 10% or more of body weight over a year cleared the steatohepatitis in about 90% of cases. Early scarring pulled back in 45%. The more weight came off, the better the result. The practical target most people are given is 7 to 10% of body weight.
A Mediterranean pattern of eating
The Mediterranean pattern of eating is built on whole foods: olive oil, fish, vegetables, legumes and whole grains. It has the most consistent effect on liver fat of any eating pattern. In a crossover trial it cut liver fat by about a third against a low-fat, high-carbohydrate diet, even when people lost no weight, while improving insulin sensitivity. The pattern lowers liver fat from the first week, before the scale has moved.
Movement, aerobic and resistance
Exercise lowers liver fat whether or not you lose weight, so it earns its place from the first week. Aerobic activity, including brisk walking, lowers liver fat directly. Resistance work does too, and it builds muscle that clears most of the glucose the liver would otherwise store as fat. Resistance work is also easier on the joints for someone carrying extra weight.
Coffee
People with fatty liver who drink coffee show lower liver fat and less scarring. Combining studies of people who already have fatty liver, coffee drinkers had roughly a third lower odds of significant scarring (RR 0.65, 95% CI 0.54-0.78). Whether coffee lowers the chance of developing fatty liver in the first place is unsettled: the same analysis found no significant difference there. The effect seems to come from caffeine and other coffee compounds working together. The coffee and caffeine page goes into the mechanism.
Cutting sugary drinks and added sugar
Fructose is converted by the liver directly into fat. Ultra-processed foods supply roughly 60% of calories in the American diet, and sugar-sweetened drinks are their single largest source of added sugar. The one-in-four rate of fatty liver tracks that supply. When teenage boys with fatty liver cut added sugar for eight weeks, the fat in their livers fell from about 25% to 17%. On their usual diet it barely moved. Following people over six years, those who drank sugar-sweetened beverages more often were more likely to develop fatty liver, and the risk climbed with each extra daily serving.
Treating the conditions that come with it
Four conditions usually travel with fatty liver: raised blood sugar, high blood pressure, abnormal cholesterol and poor sleep. Because the heart is the bigger long-term risk, treating these is part of treating the liver. Each often needs a clinician and a plan of its own.
The medicines, after the basics
Medicines for fatty liver arrived only recently. They come after the habits, because the habits work without side effects and hold up after you stop. They are options for someone who has worked at the basics and needs more. Every one was studied alongside diet and activity, added to that work.
Resmetirom (Rezdiffra) is the first drug approved for the inflammatory form, cleared in 2024. Over a year it cleared steatohepatitis in roughly a quarter to a third of people, and eased scarring in about a quarter. Both results beat a dummy pill, though most people taking it cleared neither the inflammation nor the scarring.
The GLP-1 drug semaglutide cleared the inflammation in about 59% of people against 17% on placebo in its phase 2 trial, which left the scarring question open. A larger phase 3 trial, ESSENCE, tested it over 72 weeks. The higher dose cleared steatohepatitis in about 63% against 34% on placebo, and eased scarring in about 37% against 22%, with weight down 10.5% against 2.0%.
Tirzepatide acts on two gut hormones. In its phase 2 trial, SYNERGY-NASH, steatohepatitis resolved in 44 to 62% across three doses against 10% on placebo, and scarring improved in 51 to 55% against 30%. Both incretin trials are still gathering long-term outcome data, and whether these drugs prevent cirrhosis and death is being measured now. Nausea is their most common side effect.
Pioglitazone cleared steatohepatitis in about half of people with diabetes or prediabetes, against fewer than one in five on placebo, and is a considered option in that group. Vitamin E, at a high daily dose, improved the inflammation in about 43% of people without diabetes against 19% on placebo. It is an option for that narrower group, one with its own long-term safety questions to discuss with a clinician.
Bariatric surgery for people with severe obesity does more than any of these. Five years on, inflammation had cleared in about 84% and scarring had eased in most, including some severe cases.
What To Do First
The steps below start with the low-effort wins and build toward weight loss.
The liver turns fructose straight into fat, so sweetened drinks are the first thing to go. Swapping them for water, plain tea or unsweetened coffee is the single change with the fastest visible effect on liver fat, and it costs nothing.
If you already drink coffee, keep it. Drinkers have less liver fat and less scarring. Whether starting coffee lowers your risk has not been shown.
Brisk walking most days, plus some resistance work. Exercise lowers liver fat even when the scale does not move.
Build meals around olive oil, fish, legumes, vegetables and whole grains. It moves liver fat before the scale moves.
Losing weight clears more liver fat than anything else here. Take it off gradually.
A fibrosis score (FIB-4) from a blood panel is the finding that predicts long-term outcome. Direct-to-consumer lab panels will run liver enzymes and a FIB-4 on your own schedule if your clinician has not, so you can watch the trend that matters.
Go Deeper
Two herbs have been studied for fatty liver, both ranking below the everyday levers above. Berberine, the bitter compound in Coptis (Huang Lian), lowered liver enzymes and liver fat, and helped blood sugar and cholesterol, usually alongside lifestyle change. Silymarin (milk thistle) modestly lowered liver enzymes in the blood, with a smaller and less reliable effect on the fat in the liver itself. Both were tested as add-ons to lifestyle change.
When to See Someone
Most of managing fatty liver is quiet, steady work you drive yourself. These are the signs that do warrant a doctor, some of them the same day:
- Yellowing of the skin or the whites of the eyes (jaundice), the liver can no longer clear bilirubin. Get it assessed(seek urgent care)
- Vomiting blood, or black tarry stools: bleeding from scar-swollen veins. An emergency(seek urgent care)
- A belly swelling with fluid, or new confusion, drowsiness, or a flapping tremor of the hands: signs of advanced liver disease. Same-day care(seek urgent care)
- Right-upper-abdominal pain that is severe or comes with fever, a different problem from fatty liver. Get it looked at
- A fibrosis score (FIB-4) or elastography reading in the higher range, the strongest signal of scarring. Ask for a specialist referral
- Liver enzymes that keep climbing, or a new drop in appetite with unplanned weight loss. Get these assessed
- Rapid weight loss from a crash diet alongside worsening liver blood tests: losing weight too fast can briefly inflame the liver
Most people with fatty liver never reach the scarring stages. Knowing these warning signs is simply so nothing is missed while you work at the daily habits that reverse it.
Common Questions
I was told I have fatty liver. Should I worry?
Worry less about the label and more about the stage. Fatty liver runs through four stages, and only the later, scarring stages carry real danger. The early form reverses in most people, and the bigger day-to-day threat is heart disease.
What is the difference between NAFLD and MASLD?
Same condition, newer name. In 2023 it was renamed MASLD to put the metabolic cause in the name, and the inflammatory form once called NASH became MASH.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 16 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.